Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA).
[allergic bronchopulmonary aspergillosis]
Abstract
Background
and
rationale
:
Antifungal
therapy
for
severe
asthma
with
fungal
sensitisation
(
SAFS
)
and
allergic
bronchopulmonary
aspergillosis
(
ABPA
)
remains
poorly
studied
.
We
assessed
the
efficacy
and
safety
of
NAB
as
second
and
third
line
therapy
in
SAFS
and
ABPA
.
Methods
:
21
adult
asthmatics
with
SAFS
(
n
 
=
 
11
)
and
ABPA
(
n
 
=
 
10
)
who
had
either
failed
itraconazole
(
n
 
=
 
8
)
,
voriconazole
proceeded
by
itraconazole
(
n
 
=
 
5
)
or
developed
adverse
events
(
AEs
)
to
either
agent
(
n
 
=
 
7
)
were
treated
with
10
mg
of
NAB
(
Fungizone
)
twice
daily
.
We
audited
clinical
and
immunological
response
,
using
the
Asthma
Quality
of
Life
Questionnaire
(
AQLQ-J
)
scores
,
asthma
control
,
FEV
1
,
healthcare
utilisation
and
IgE
.
Patients
were
followed
up
for
12
months
.
Results
:
Twenty
-
one
patients
were
treated
(
SAFS
,
n
 
=
 
11
)
and
(
ABPA
,
n
 
=
 
10
)
,
M
:
F
 
=
 
8
:
12
,
median
age
65
years
(
range
,
24
-
78
)
.
The
median
duration
of
therapy
was
30
days
(
0
-
1825
)
.
Clinical
benefit
was
observed
in
three
(
14
.
3
%
)
in
which
overall
mean
AQLQ-J
score
improved
by
 
+
 
2
.
9
,
mean
FEV
1
improved
by
0
.
5
L
and
there
was
improvement
in
overall
asthma
control
.
Seven
(
33
%
)
failed
initial
dose
(
bronchospasm
)
.
Eleven
(
52
.
4
%
)
discontinued
within
12
months
of
therapy
due
to
delayed
bronchospasm
(
n
 
=
 
3
,
within
4
weeks
)
,
equipment
problems
(
n
 
=
 
2
,
within
4
weeks
)
and
lack
of
clinical
benefit
(
n
 
=
 
4
,
within
16
weeks
)
.
Conclusion
:
Our
data
suggest
that
the
overall
efficacy
of
NAB
in
this
group
of
patients
is
poor
and
associated
with
bronchospasm
.
However
,
the
excellent
response
in
3
patients
,
suggest
it
may
be
considered
when
other
alternatives
have
been
exhausted
.
Overcoming
the
initial
bronchospasm
may
improve
tolerability
.
Diseases
Validation
Diseases presenting
"delayed bronchospasm"
symptom
allergic bronchopulmonary aspergillosis
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom